BioAtla hosting R&D Day to highlight BA3071 CAB-CTLA-4 Phase 1 data

BioAtla is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent. Key R&D Day Topics and Highlights: Preclinical data review of targeted, pH-dependent binding of BA3071 in the tumor microenvironment demonstrated complete tumor regression following BA3071 treatment. A Phase 1 dose-escalation study evaluated BA3071 monotherapy followed by combination with nivolumab, conducted in 18 patients who had prior PD-1 failure and a median of at least three prior lines of treatment: Across the 6 cohorts, best overall response observed with two confirmed responses; nine stable disease; More specifically, in the 350 mg cohort in combination with 240 mg nivolumab, meaningful clinical benefit was observed in three patients, including 1 CR, 1 PR, and 1 SD; No grade 4 related treatment-emergent adverse events were observed among 18 treated patients. A Phase 2 clinical study of BA3071 monotherapy and in combination with PD-1 inhibitor is currently underway